Ann: Trading Halt, page-55

Interferon and Ribavirin are completely outdated as a standard of care for HCV. Biotron have used them to try and prove their drug but during this time the DAAs have taken the standard to another level. The cure was nearly as bad as the disease. Both drugs have serious issues.

I think the interest in HIV has been regenerated with this latest announcement.

One pill, once a day is CURING many patients of HCV in eight weeks. Even the new GS-5816 looks like it will treat relapsers, non responders, G3 and the cirrhotics with aplomb...... Making BIT225 a questionable approach for HCV combinations. Let's see who and how they end up partnering wi the DAA trial. Maybe they will go for dual infected patients as an arm of the study.

As I said previously, nothing is gained until SVR12 is achieved.